"The Company is currently completing the enrollmen
Post# of 30028
Posted On: 08/24/2014 6:58:30 PM
Quote:
"The Company is currently completing the enrollment of its LP-002 clinical study, and based on the interim data will likely increase the number of subjects entered in the study in order to properly power certain key data aspects that were emerging in the interim data set and may add significant value to LymPro on a near-term basis. We are on track to announce full data sets for LymPro later this quarter (3Q14)"
See more at:
http://www.thechairmansblog.com/amarantus-bio...iqU0s.dpuf
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼